# Clinical trials using genome editing based therapeutics and gene delivery therapies

**Successfully audited by the FDA, EMA and Health Canada**

## *LPL*-gene replacement therapy (Glybera)

The first in-human gene therapy to reach the market

- Co-development
- Execution of pivotal trials
- Publications
- 15 years Follow-up

## Next generation *LPL*-gene replacement therapy

With the National Research Council Canada (NRC)

- Co-development
- Clinical Sponsor

## Human gene editing clinical trials

Verve therapeutics, Undisclosed

- Scientific Input
- Clinical Input
- Regulatory Input
- Execution

## Multiple Phase IIa and Investigator-initiated studies

- Conception
- Conduct

- SCIENTIFIC OUTPUTS
- REGULATORY-RELATED EXPERIENCE
- REMOTE MONITORING CAPABILITIES
- PoC-PHASE III

contact@ecogene21.org
ecogene-21

ecogene21